Mycophenolate mofetil may be an alternative for maintenance therapy of Behçet syndrome uveitis: a single-center retrospective analysis

Ucar, Didar; Esatoglu, Sinem Nihal; Cerme, Emir; Batu-Oto, Bilge; Hamuryudan, Vedat; Seyahi, Emire; Melikoglu, Melike; Fresko, Izzet; Ozyazgan, Yılmaz; Hatemi, Gulen

doi:10.1007/s00296-023-05420-4

Rheumatol Int

2023

DOI: 10.1007/s00296-023-05420-4

|View full text |Cite

Mycophenolate mofetil may be an alternative for maintenance therapy of Behçet syndrome uveitis: a single-center retrospective analysis

Didar Ucar,

Sinem Nihal Esatoglu,

Emir Cerme

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2023

2024

Publication Types

Select...

Article3

Relationship

Self Cite0

Independent3

Authors

Journals

Cited by 3 publications

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Disease and Treatment-Specific Complications of Behçet Syndrome

Esatoglu,

Ozguler,

Hatemi

2023

Curr Rheumatol Rep

View full text Add to dashboard Cite

Disease and Treatment-Specific Complications of Behçet Syndrome

Esatoglu,

Ozguler,

Hatemi

2023

Curr Rheumatol Rep

View full text Add to dashboard Cite

Recent advances in the diagnosis and management of Behçet’s syndrome uveitis

Kechida,

Bazewicz,

Nabi

et al. 2024

Expert Review of Ophthalmology

View full text Add to dashboard Cite

Adamantiades‐Behcet's disease: From the first known descriptions to the era of the biologic agents

Stefanadi,

Dimitrakakis,

Dimitrakaki

et al. 2024

Int J of Rheum Dis

View full text Add to dashboard Cite

In 1937, Dermatologist Hulusi Behcet presented a case of a patient with a 7-year history of recurrent ocular lesions, oral aphthous ulcers, and genital ulcers. The case report with the addition of a similar one was published in 1937. 1 Behcet published three more relevant papers most importantly pointing toward a single disease-syndrome from 1938 to 1940. In 1930, the Ophthalmologist Benedictos Adamantiades had described a case report of a disease with the title "A case of relapsing iritis with hypopyon." 2 Interestingly, we find Adamantiades-Behcet's disease (ABD) descriptions not only from Hippocrates of Kos but also from clinical observations similar to ABD disease recorded from 1772 to 1940. 3,4 Adamantiades-Behcet's disease (ABD) is a chronic, multisystem inflammatory disorder, which is clinically characterized mainly by relapsing oral aphthous, genital ulcers, ocular, and vascular lesions.The disease may affect small and large vessels in almost all organs. B-cell inhibitorsRituximab for ocular involvement Interleukin inhibitors monoclonal antibodiesAnakinra (IL 1) Canakinumab (IL1) Mucocutaneous involvement Ustekinumab (IL 12, IL 23) Tocilizumab (IL 6) Selective costimulation modulators Abatacept ocular, cutaneous involvement Apremilast phosphodiesterase inhibitor PDE4 Anti TNF Adalimumab, Infiximab eye, deep vein thrombosis, GI involvement, nervous system involvement Etanercept arthritis, mucocutaneous involvement TA B L E 2 Categories of biologic agents under study and in use.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Mycophenolate mofetil may be an alternative for maintenance therapy of Behçet syndrome uveitis: a single-center retrospective analysis

Cited by 3 publications

References 30 publications

Disease and Treatment-Specific Complications of Behçet Syndrome

Disease and Treatment-Specific Complications of Behçet Syndrome

Recent advances in the diagnosis and management of Behçet’s syndrome uveitis

Adamantiades‐Behcet's disease: From the first known descriptions to the era of the biologic agents

Contact Info

Product

Resources

About